Company Overview and News

 
D-Street Buzz: IT stocks gain led by Oracle Financial; sugar stocks continue to rally, RIL drags

2018-09-17 moneycontrol
The Indian stock market have extended the morning loses and are trading well in the red this Monday afternoon with the Nifty50 down 102 points and is trading at 11,412 while the Sensex is trading lower by 391 points at 37,699.
GRASIM IOC 500408 SUZLON 500325 BRTQY TCHQY 532755 SONATSOFTW 532480 500696 BJJQY BRITANNIA SUEL RLNIY 504212 SBAZ GRSJY 524804 UNITDSPR ALBK YYBKY 530965 532667 TECHM 532432 BAJFINANCE TATASTEEL TATLY UQNTY 500300 500825 AUROPHARMA 533271 GODREJIND RELIANCE 512573 HINDUNILVR ASHOKA 532221 500470 RIGD SAKHTISUG UNIVCABLES 500034 YESBANK UBNC AVANTI 532648 GRSXY TTST ARBQY TATAELXSI 507315 500164

 
Central Bank moves tribunal against SEBI order

2018-09-12 thehindubusinessline
Our Bureau The Central Bank of India has moved the Securities Appellate Tribunal on Tuesday contesting the ₹3-lakh penalty imposed on it by SEBI.
500825 BRTQY BRITANNIA

 
Consumers will have to shell out more for daily-use products as FMCG firms hike prices by 5-8%: Report

2018-09-07 moneycontrol
Higher minimum support price (MSP) and record fuel hike will soon make daily-use products costlier as fast moving consumer goods (FMCG) companies will increase prices by 5-8 percent, reports The Economic Times.
500825 BRTQY 500696 HINDUNILVR BRITANNIA

 
Britannia, HUL shares fall 2-3% after Credit Suisse downgrades to Neutral

2018-09-05 moneycontrol
Global investment firm Credit Suisse downgraded Britannia Industries and Hindustan Unilever to Neutral, which pushed both stocks down by 2.65 percent and 2 percent intraday respectively on Wednesday.
500825 BRTQY 500696 NESTLEIND HINDUNILVR BRITANNIA NSZTY 500790

 
ITC plans to take on Amul, Britannia, Coke with milk-based beverages

2018-09-04 moneycontrol
The ready-to-drink, milk-based beverage space is likely to see heightened competition ahead among players such as Amul, Britannia Industries and Coca-Cola as ITC looks to foray into this space. The Kolkata-based multi-business enterprise is set to launch its new product range - Sunfeast Wonderz - next month, as per a report in The Economic Times.
500825 BRTQY BRITANNIA

 
D-Street Buzz: FMCG stocks fall dragged by Jubilant Food, HUL; IT stocks rally with Infosys up 3%, hits new 52-week high

2018-09-04 moneycontrol
The market sentiment is negative this Tuesday morning after the rupee slipped to yet another record low against the US dollar. The benchmark indices including the Nifty50 shed 42 points at 11,540 while the Sensex is trading lower by 86 points at 38,226.
500325 DABUR BRIGADE BRTQY TCHQY TTQQY 532755 DBRQY 532710 TATACHEM SYNDIBANK 500096 532483 500696 BRITANNIA 500770 502355 RLNIY SBAZ RELCAPITAL YYBKY 530005 ALBERTDA CNRYY TECHM 532276 TCS CANBK ANDHRABANK BALKRISIND 500825 RELIANCE 532418 HINDUNILVR 533155 TATACOMM NAUKRI TTNQY JUBLFOOD 532777 532540 RIGD JBLWY SADBHAV INDIACEM 500111 YESBANK UBNC 517354 HVLQY 532929 532648 524075 HAVELLS 501455 GREAVESCOT 500483

 
Britannia Industries to split stock in 1:2 ratio

2018-08-23 livemint
New Delhi: The board of Britannia Industries on Thursday approved a share split in 1:2 ratio to make the stock more affordable for small retail investors and increase liquidity. The Kolkata-based company will split shares with a face value of Rs 2 into two equity shares of Re 1 each.
500825 BRTQY BRITANNIA

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...